Paolo A. Ascierto

Address National Tumour Institute “Fondazione G. Pascale” Unit of Melanoma
Cancer Immunotherapy and Innovative therapy
Naples
Country

Italy

Paolo Ascierto

Paolo A. Ascierto obtained his medical degree from the University of Naples, Italy, the institution where he subsequently earned his Board Certification in Oncology. He went on to serve consecutive positions at the National Tumour Institute “Fondazione G. Pascale”, in Naples,  as a postdoctoral fellow and then as Vice Director of the Department of Clinical Immunology.  Professor Ascierto is currently Director of the Unit of Melanoma, Cancer Immunotherapy and Innovative therapy at that same institution.  He is an active Scientific Reviewer for several international journals, including, JCO, Lancet Oncology, and Clinical Cancer Research, as well as being the Editor-in-Chief of the Combination Strategies section of the Journal of Translational Medicine and Chief Section Editor of Expert Reviews of Immunology Vaccines and Informatics. As a result of Professor Ascierto’s experience and expertise, he has been a valued invited speaker at more than 350 national and international meetings. Furthermore, he is an active member of the Italian Society of Medical Oncology (AIOM), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), European Organization for Research and Treatment of Cancer (EORTC) and Society of Immuno Therapy of Cancer (SITC). Professor Ascierto has presided as Principal Investigator on over 50 clinical trials and he is the author of numerous publications in peer-reviewed journals. Such journals include: The New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, and Clinical Cancer Research, among others.

Primarily, his major research interests are the genetics and proteomics of melanoma, the assessment of molecular markers for tumour progression in melanoma, management of targeted therapies for melanoma, vaccination treatments and immunotherapy of cancer, biochemical and immunological monitoring, and combination approaches for the cancer treatment.